ChromoCare, founded in 2014, is dedicated to advancing the practice of medicine through personalized care. The company aims to make reliable and affordable diagnostic testing accessible to healthcare providers, with the ultimate goal of reducing adverse drug reactions, cutting costs, and enhancing patient outcomes. One of Chromocare's significant contributions is the introduction of The Genetic Assisted Prescribing (GAP) Test, which allows healthcare providers to replace the conventional "trial and error" prescribing method with a more effective, genetically-informed treatment plan tailored to each patient. This test is touted as the most comprehensive drug compatibility test available, positioning Chromocare as an emerging leader in the pharmacogenetic testing field within the Biotechnology and Health Care industries. To gain insights into Chromocare's pioneering role in precision medicine, interested parties can visit www.TheGAPTest.com.
There is no investment information
No recent news or press coverage available for ChromoCare.
We care about your data, and we'd love to use cookies make your experience better.
